Identifying and Characterising Response in Clinical Trials: Development and Validation of a Machine Learning Approach in Colorectal Cancer
Precision medicine promises to transform health care by offering individualised treatments that dramatically improve clinical outcomes. A necessary prerequisite is to identify subgroups of patients who respond differently to different therapies. Current approaches are limited to static measures of treatment success, neglecting the repeated measures found in most clinical trials. Our approach combines the concept of partly conditional modelling with treatment effect estimation based on the Virtual Twins method. The resulting time-specific responses to treatment are characterised using survLIME, an extension of Local Interpretable Model-agnostic Explanations (LIME) to survival data. Performance was evaluated using synthetic data and applied to clinical trials examining the effectiveness of panitumumab to treat metastatic colorectal cancer. An area under the receiver operating characteristic curve (AUC) of 0.77 for identifying fixed responders was achieved in a 1000 patient simulation. When considering dynamic responders, partly conditional modelling increased the AUC from 0.597 to 0.685. Applying the approach to colorectal cancer trials found genetic mutations, sites of metastasis, and ethnicity as important factors for response to treatment. Our approach can accommodate a dynamic response to treatment while potentially providing better performance than existing methods in instances of a fixed response to treatment. When applied to clinical data we attain results consistent with the literature.
Code (0)
등록된 구현이 없습니다.
Similar Papers 제목 키워드 기반
The Future will be Different than Today: Model Evaluation Considerations when Developing Translational Clinical Biomarker
Finding translational biomarkers stands center stage of the future of personalized medicine in healthcare. We observed notable challenges in identifying robust biomarkers as some with great performance in one scenario of…
Identifying treatment response subgroups in observational time-to-event data
Identifying patient subgroups with different treatment responses is an important task to inform medical recommendations, guidelines, and the design of future clinical trials. Existing approaches for treatment effect esti…
MatchMiner-AI: An Open-Source Solution for Cancer Clinical Trial Matching
Clinical trials drive improvements in cancer treatments and outcomes. However, most adults with cancer do not participate in trials, and trials often fail to enroll enough patients to answer their scientific questions. A…
A Deep Subgrouping Framework for Precision Drug Repurposing via Emulating Clinical Trials on Real-world Patient Data
Drug repurposing identifies new therapeutic uses for existing drugs, reducing the time and costs compared to traditional de novo drug discovery. Most existing drug repurposing studies using real-world patient data often …
Drug DiscoverySECRET: Semi-supervised Clinical Trial Document Similarity Search
Clinical trials are vital for evaluation of safety and efficacy of new treatments. However, clinical trials are resource-intensive, time-consuming and expensive to conduct, where errors in trial design, reduced efficacy,…